Press Releases

Press Releases
Date Title and Summary View
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that updated data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the 52nd Annual Meeting of the American Society of Hematology....
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that its next IMiD® compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatm...
Dec 5, 2010 BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the 52nd A...
Dec 5, 2010 BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX®) in progressive or relapsed PTCL following prior ...
Dec 4, 2010 BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the use of REVLIMID® (lenalidomide) either with rituximab or following a rituximab-containing ...
Dec 4, 2010 BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma...
Nov 30, 2010 BOUDRY, Switzerland, Nov 30, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in more than 260 posters and presentations, including more than 65 oral presentations evaluating Celgene ...
Nov 26, 2010 SUMMIT, N.J., Nov 26, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30, 2010 at 9:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at ...
Nov 9, 2010 SUMMIT, N.J., Nov 09, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at ...
Oct 29, 2010 SUMMIT, N.J., Oct 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at Oppenheimer's 21st Annual Healthcare Conference on Tuesday, November 2, 2010 at 11:25 a.m. ET will be webcast live and will be available in the investor relations section of the ...
FirstPrevious ...
45
... NextLast
Add to Briefcase = add release to Briefcase